Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has been added to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes NASDAQ-listed companies in the biotechnology and pharmaceutical sectors that meet specific eligibility criteria. Mirum is focused on treating rare liver diseases, with its approved drug LIVMARLI™ for cholestatic pruritus in Alagille syndrome patients. The company is also developing investigational treatments and has acquired options for gene therapies targeting PFIC types 2 and 3.
Mirum Pharmaceuticals presented new analyses from clinical studies of LIVMARLI™ at the NASPGHAN Annual Meeting. The studies focused on children with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC2). In the ICONIC study, 74% of patients showed improvement in pruritus, correlating with enhancements in health-related quality of life (HRQoL) measures, including fatigue and sleep disturbances. Additionally, patients with PFIC2 achieving serum bile acid response also noted significant HRQoL improvements. These findings highlight LIVMARLI's potential in treating rare liver diseases.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced the presentation of five posters on LIVMARLI™ (maralixibat) at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting from December 12-18, 2021. Key studies highlight the treatment's impact on health-related quality of life for patients with Alagille syndrome and BSEP deficiency. The abstracts are accessible via the NASPGHAN website, and LIVMARLI is recognized as a breakthrough therapy for certain cholestatic liver diseases.
Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in two upcoming virtual investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021, will include a fireside chat available from November 22. The 4th Annual Evercore ISI HealthconX Conference is scheduled for December 2, with a fireside chat at 3:30 p.m. ET. Mirum specializes in treatments for rare liver diseases, including LIVMARLI (maralixibat), approved for cholestatic pruritus in Alagille syndrome. The company is developing investigational treatments for various liver conditions.
Mirum Pharmaceuticals (MIRM) announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $110 million. This PRV was granted by the U.S. FDA in September 2021 for LIVMARLI™, a treatment for cholestatic pruritus in Alagille syndrome. The company expects to receive the payment upon closing the transaction, pending U.S. antitrust clearance. Jefferies LLC acted as the exclusive financial advisor for this transaction.
Mirum Pharmaceuticals announced the U.S. commercial launch of LIVMARLI™, the first approved treatment for cholestatic pruritus in Alagille syndrome (ALGS) patients aged one and older. The FDA approval marks a pivotal moment for the company, supported by a robust financial position with $205 million in cash. Significant clinical data was presented, showing improved six-year event-free survival rates (p<0.0001) and durable responses in pruritus from the pivotal ICONIC study. Despite a net loss of $47.1 million for Q3 2021, Mirum aims for sustained growth with an advancing clinical pipeline.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) presented a new analysis of its drug LIVMARLI™ (maralixibat) at The Liver Meeting®, showing statistically significant improvements in six-year event-free survival and transplant-free survival for patients with Alagille syndrome (ALGS) (p<0.0001). The study, conducted by the Global Alagille Alliance (GALA), compared LIVMARLI's clinical trial data against a natural history cohort, indicating a 70% reduction in adverse clinical outcomes. These results support LIVMARLI's potential as a significant treatment for ALGS patients, especially in delaying liver transplants.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will report its financial results for Q3 2021 on November 15, 2021, at 1:30 p.m. PT. A conference call and audio webcast will follow to discuss the results and business updates. Mirum is focused on treating rare liver diseases with its approved drug LIVMARLI™ and investigational treatments. The company is advancing its late-stage pipeline, which includes pivotal studies for conditions like Alagille syndrome and biliary atresia.
Mirum Pharmaceuticals (MIRM) announced the presentation of new data for LIVMARLI (maralixibat) at the American Association for the Study of Liver Diseases annual congress from November 12-15, 2021. The highlights include a late-breaker oral presentation on a six-year event-free survival analysis in Alagille syndrome, selected for Best of the Liver Meeting. Additionally, a second late-breaker presentation will showcase predictors of long-term survival in patients treated with maralixibat. LIVMARLI is FDA-approved for cholestatic pruritus in Alagille syndrome.
Mirum Pharmaceuticals recently announced significant findings regarding its drug maralixibat, published in The Lancet. The four-year study shows that maralixibat offers durable improvements in cholestasis parameters, including pruritus, for children with Alagille syndrome. The drug demonstrated a robust clinical response with >80% of participants experiencing a reduction in pruritus. Approved by the FDA as LIVMARLI, maralixibat is pivotal for treating this rare liver condition. Mirum aims to further expand its market presence in Europe.